Alector, Inc. — Q1 2022 Form 10-Q
Business context and reporting period
Clinical-stage biopharmaceutical company focused on immuno-neurology and therapies for neurodegenerative diseases. This filing covers the three months ended March 31, 2022; comparisons are with Q1 2021 unless noted. Alector had no approved products and generated no product-sales revenue. Collaboration revenue came primarily from GSK and AbbVie.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Collaboration revenue | $24.5 million | $4.1 million |
| Research and development expense | $53.0 million | $45.7 million |
| General and administrative expense | $15.6 million | $11.0 million |
| Net loss | $44.6 million | $52.2 million |
| Net loss per share, basic and diluted | $0.54 | $0.66 |
| Operating cash flow | +$135.1 million | −$52.7 million |
| Cash, cash equivalents and marketable securities | $868.6 million | $735.3 million at December 31, 2021 |
| Total assets / total liabilities | $954.5 million / $686.9 million | $814.7 million / $513.9 million at December 31, 2021 |
Operating loss was $44.1 million, versus $52.6 million in Q1 2021. The company reported $3.0 million of unrealized investment losses in other comprehensive loss. As a clinical-stage company, conventional product gross margins are not applicable. The filing reports no borrowings; operating lease liabilities totaled approximately $46.6 million. Deferred revenue was $600.7 million, including $486.7 million related to GSK, and is not debt.
Material changes versus the prior comparable period
- Revenue increased by $20.4 million, primarily from recognition of GSK collaboration revenue; GSK revenue was $21.2 million in Q1 2022. AbbVie revenue was $3.3 million, down from $4.1 million, partly reflecting revised expected program costs.
- Operating expenses rose $11.9 million. R&D increased $7.3 million, driven by higher personnel, early-stage program and facility costs, partly offset by lower costs in certain partnered programs. G&A increased $4.5 million, primarily from personnel and legal costs.
- Operating cash flow swung to positive $135.1 million, largely because Alector received the second $200 million installment of GSK’s upfront payment in January 2022. The payment increased deferred revenue; it does not represent recurring operating cash generation.
- Cash, cash equivalents and marketable securities increased from $735.3 million at year-end. Accumulated deficit was $491.0 million at March 31, 2022.
Outlook, management commentary and key risks
- Management estimates current cash, cash equivalents and marketable securities will fund operations and capital expenditure requirements into mid-2024, based on assumptions that may prove inaccurate. The company expects expenses to rise and anticipates needing substantial additional funding in the future.
- GSK may provide up to an additional $1.5 billion in clinical, regulatory and commercial milestones, subject to achievement. Under the collaboration, Alector and GSK share U.S. commercialization profits and losses; outside the U.S., GSK leads commercialization and Alector may receive tiered royalties.
- Latozinemab is being studied in the pivotal Phase 3 INFRONT-3 trial for FTD-GRN. Management reported encouraging earlier-stage biomarker and clinical observations, which are not evidence of Phase 3 success. Enrollment in the latozinemab ALS study was closed by strategic decision while a possible broader Phase 2b study was evaluated.
- In the AL002 Phase 2 Alzheimer’s trial, ARIA was observed. Most reported cases were asymptomatic and non-serious, but a small number of serious adverse events occurred in APOE e4/e4 participants. Dosing and enrollment of this genotype were discontinued; Alector planned a protocol amendment to exclude these participants and was assessing effects on enrollment timing.
- AL101 Phase 1 data were expected in the second half of 2022; Alector expected to initiate an AL044 first-in-human trial in the second half of 2022. Innovent expected to begin AL008 first-in-human studies in China in 2022; Alector planned to advance AL009 into clinical studies within the following year. These were forward-looking plans, not reported outcomes.
- Management cited risks including clinical-trial failure or delay, safety and regulatory uncertainty, reliance on collaborators and third-party manufacturers, COVID-19-related site and supply disruptions, inflation and competitive hiring costs, and the need for future financing. The filing reported no legal proceedings management considered likely to have a material adverse effect.
Important facts for investors to verify
- Progress, safety findings and enrollment timing for INFRONT-3 and INVOKE-2, including the effects of the APOE e4/e4 protocol changes.
- Whether AL101 data, AL044 trial initiation and planned AL008 and AL009 studies occurred on the timelines described.
- Cash burn excluding collaboration advances, updated runway assumptions, and whether additional financing becomes necessary.
- GSK and AbbVie collaboration milestones, cost sharing, revenue recognition and the effect of updated program-cost estimates on deferred revenue and reported revenue.
- Whether clinical, manufacturing, COVID-19, inflation or staffing risks materially affect development costs, trial integrity or timelines.